CD274 and neoplasm: Currently, the testing of PDL1 expression in the tumor microenvironment [5] and testing for the presence of mismatched repair deficiency in tumor cells [103], which correlates with microsatellite instability and tumor mutational burden, have been approved by the FDA for guidance of ICI therapy in clinics.